News
No Christmas present for Sanofi, as FDA turns down MS drug
FDA has turned down Sanofi's oral BTK inhibitor tolebrutinib for multiple sclerosis, despite suggesting earlier it would delay a decision until 2026.
Wednesday 1 April 2026
